TOKYO -- Japan's health ministry is preparing to formally approve as early as Monday the manufacture and sale of an Alzheimer's drug developed by Japanese pharmaceutical company Eisai and U.S. partner Biogen.
Pharmaceuticals
Japan set to approve Alzheimer's drug Leqembi as soon as Monday
Eisai-Biogen treatment clears fast-track review after U.S. green light in August
Lecanemab, branded as Leqembi, has been shown in trials to slow the rate of disease progression by 27%. (Photo courtesy of Eisai)
Read Next
%2520%E3%81%AE%E3%82%B3%E3%83%94%E3%83%BC.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
